Less Ads, More Data, More Tools Register for FREE

Total Voting Rights

17 Apr 2020 09:46

RNS Number : 0246K
Cello Health PLC
17 April 2020
 

17 April 2020

 

Cello Health plc

("Cello" or the "Company")

 

Total Voting Rights

 

As at today's date, Cello's issued share capital comprises 106,828,473 ordinary shares of 10 pence each ("Ordinary Shares"), of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company is therefore 106,375,473 Ordinary Shares.

 

The above figure (106,375,473 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Group Finance Director

www.cellohealthplc.com

Cenkos Securities plc

020 7397 8900

Giles Balleny

Harry Hargreaves

Buchanan

Mark Court

020 7466 5000

Jamie Hooper

Sophie Wills

 

 

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading scientific, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia, New Jersey, London, Edinburgh, and Farnham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRVDLBFBZLZBBE

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS